Sata Akira, Ho Ken K Y
Department of Endocrinology, St Vincent's Hospital and the Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia.
Pituitary. 2007;10(2):165-72. doi: 10.1007/s11102-007-0034-x.
Before the availability of immunoassays for IGF-I, growth hormone (GH) measurement was the sole method used in the biochemical assessment of acromegaly. IGF-I has since been established as the most reliable biochemical indicator of acromegaly. The last 25 years has seen important advances in the understanding of the neuroregulation and in the characterization of GH secretion in acromegaly. The availability of supersensitive GH has changed many aspects of the interpretation of GH-value in the management of acromegaly. Hypersecretion and abnormal neuroregulation characterize GH secretion in acromegaly. GH can be measured in many ways: as a single random sample, as multiple samples, either spontaneously or as an integral part of a dynamic test. These approaches give useful information on diagnosis, therapy, and prognosis. There is a place for measuring GH in the management of acromegaly although it complements that of IGF-I.
在可进行胰岛素样生长因子-I(IGF-I)免疫测定之前,生长激素(GH)测量是肢端肥大症生化评估中唯一使用的方法。自那时起,IGF-I已被确立为肢端肥大症最可靠的生化指标。在过去25年里,对肢端肥大症中神经调节的理解以及GH分泌特征的认识取得了重要进展。超灵敏GH的出现改变了肢端肥大症管理中对GH值解读的许多方面。GH分泌过多和异常神经调节是肢端肥大症中GH分泌的特征。GH可以通过多种方式测量:作为单次随机样本、多个样本,可自发测量或作为动态试验的一个组成部分。这些方法为诊断、治疗和预后提供了有用信息。在肢端肥大症的管理中,测量GH是有意义的,尽管它是对IGF-I测量的补充。